Sajjad Ali, Hameed Sajid, Khan Sara
Ali Sajjad, MBBS, FCPS (Neurology) Department of Medicine, Neurology Section, Aga Khan University and Hospital Karachi, Pakistan.
Sajid Hameed, MBBS, FCPS (Neurology) Department of Medicine, Neurology Section, Aga Khan University and Hospital Karachi, Pakistan.
Pak J Med Sci. 2024 Sep;40(8):1669-1674. doi: 10.12669/pjms.40.8.7719.
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an acquired treatable autoimmune disorder. Due to limited availability and affordability of IV immunoglobulins and therapeutic plasma exchange in Pakistan, oral immunosuppressive drugs (ISDs) are used despite limited role in literature. The study aimed to determine the response to ISDs in CIDP patients by assessing the frequency of remission, reduction of disability using a neuropathy related disability score called Inflammatory Neuropathy Cause and Treatment score (or INCAT score), as well as reduction in steroid maintenance dose.
The retrospective observational study of six months duration (May to October, 2020) was carried out in Aga Khan University Hospital, Karachi, Pakistan. Medical record of all the patients with idiopathic CIDP taking oral ISDs in last five years was selected which included bio-data, clinical signs and symptoms, medication details, and INCAT scores. Descriptive statistics were described i.e. frequency, percentages, mean/standard deviation using Microsoft Excel v.2021.
Out of thirteen patients, Azathioprine was used in nine, Mycophenolate mofetil in two and Cyclosporine in two, with remission (INCAT score improvement ≥ 1) achieved in eight, one and zero patients respectively. Duration of ISDs ranged from three to twenty-four months (average 15.8 months). Patients with monoclonal paraproteinemia and prior exposure to ISDs had a poor response to the introduction of subsequent ISDs.
The study describes preliminary experience of the potential role of relatively cheaper and more convenient oral ISDs (especially Azathioprine) as an alternative or sparing agent to first line agents for CIDP and sets the stage for larger scale studies and randomized controlled trials.
慢性炎症性脱髓鞘性多发性神经根神经病(CIDP)是一种可治疗的获得性自身免疫性疾病。由于在巴基斯坦静脉注射免疫球蛋白和治疗性血浆置换的可及性和可负担性有限,尽管文献中其作用有限,但仍使用口服免疫抑制药物(ISDs)。本研究旨在通过评估缓解频率、使用一种称为炎症性神经病病因与治疗评分(或INCAT评分)的神经病相关残疾评分来降低残疾程度,以及降低类固醇维持剂量,来确定CIDP患者对ISDs的反应。
在巴基斯坦卡拉奇的阿迦汗大学医院进行了为期六个月(2020年5月至10月)的回顾性观察研究。选取了过去五年中所有服用口服ISDs的特发性CIDP患者的病历,包括生物数据、临床体征和症状、用药细节以及INCAT评分。使用Microsoft Excel v.2021进行描述性统计,即频率、百分比、均值/标准差。
13例患者中,9例使用硫唑嘌呤,2例使用霉酚酸酯,2例使用环孢素,分别有8例、1例和0例患者实现缓解(INCAT评分改善≥1)。ISDs的使用时间为3至24个月(平均15.8个月)。患有单克隆副蛋白血症和既往接触过ISDs的患者对后续引入的ISDs反应较差。
本研究描述了相对便宜且更方便的口服ISDs(尤其是硫唑嘌呤)作为CIDP一线药物的替代或节省药物的潜在作用的初步经验,并为更大规模的研究和随机对照试验奠定了基础。